BioAtla, Inc.

BioAtla, Inc.

Safer, more effective drugs for cancer using a proprietary next generation antibody discovery and evolution platform

Founded 2007

San Diego, United States 35 employees IPO Total: $493.00M Biotechnology, Health Care

BioAtla is a protein therapeutic company utilizing discovery and evolution to develop safer and more potent drugs for cancer treatment. The company's expertise, backed by 150+ patents and patent applications, culminates in its Conditionally Active Biologics (CAB) platform, enabling the engineering of monoclonal antibodies and biologics for selective conditional activation. This innovation, such as preferential binding under the unique conditions of the tumor microenvironment, enhances tumor selectivity, addressing on-target toxicity and improving the therapeutic index. Founded in 2007 and headquartered in the United States, BioAtla is focused on applying these technologies in its pipeline and partnerships to deliver improved immunotherapies for cancer. The last investment round amounted to $65.00M in Post-IPO Equity and was made on 04 November 2022, with participation from prominent investors like Vivo Capital, Acuta Capital, Adage Capital Management, Cormorant Asset Management, EcoR1 Capital, Janus Handerson, and Soleus Capital.

Funding Stage	Amount	Investors	Lead Investors	Date
Post-IPO Debt	$7.50M	1	Yorkville Advisors	01 Nov 2025
Post-IPO Equity	$65.00M	5	Adage Capital Management, Cormorant Asset Management +3	01 Nov 2022
Post-IPO Equity	$75.00M	6	Pappas Capital, Hudson Bay Capital +4	01 Sep 2021
IPO	$189.00M	-		01 Dec 2020
Series D	$72.50M	8	HBM Healthcare Investments, Boxer Capital +6	01 Jul 2020
Early VC	$45.00M	-		01 Jan 2016
Early VC	$39.00M	-		01 Jul 2015

Funding Stage

Amount

Investors

Lead Investors

Date

Post-IPO Debt

$7.50M

Yorkville Advisors

01 Nov 2025

Post-IPO Equity

$65.00M

Adage Capital Management, Cormorant Asset Management +3

01 Nov 2022

Post-IPO Equity

$75.00M

Pappas Capital, Hudson Bay Capital +4

01 Sep 2021

IPO

$189.00M

01 Dec 2020

Series D

$72.50M

HBM Healthcare Investments, Boxer Capital +6

01 Jul 2020

Early VC

$45.00M

01 Jan 2016

Early VC

$39.00M

01 Jul 2015

FAQ About BioAtla, Inc.

Safer, more effective drugs for cancer using a proprietary next generation antibody discovery and evolution platform

BioAtla, Inc. was founded in 2007.

BioAtla, Inc. is headquartered in San Diego, United States.

BioAtla, Inc. operates in Biotechnology and Health Care. Its work centres on Protein Therapeutics, Cancer Treatment, Discovery and Evolution.

BioAtla, Inc. has approximately 35 employees.

BioAtla, Inc. has completed 7 funding rounds, raising a total of $493.00M. The latest funding stage is IPO.

Top alternatives and competitors to BioAtla, Inc. include Sensei Bio, OncoResponse, ImmunoBiochem Corporation, Farcast Biosciences, Cytimmune Sciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

BioAtla, Inc. and Sensei Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About BioAtla, Inc.

Funding Rounds & Investors (7)

BioAtla, Inc. Alternatives & Competitors

FAQ About BioAtla, Inc.